Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers

NCT ID: NCT00626158

Last Updated: 2012-04-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-02-29
• Study Completion Date: 2010-12-31

Brief Summary

The purpose of this study is to find out what effects gemcitabine plus capecitabine has on patients with pancreatic or biliary cancer, and to determine the optimal dose that can be given safely of these two drugs together (called the maximum tolerated dose). Gemcitabine and capecitabine are two chemotherapy drugs used to treat pancreatic and biliary cancer. These two drugs used together are considered an acceptable standard of care for pancreatic and biliary cancers. However, in this study the dose and dosing schedule will be changed, in the hopes that the drugs will have more effect with fewer side effects than when given in the standard way.

Conditions

Pancreatic Cancer; Biliary Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Gem/Cape

Group Type: EXPERIMENTAL

gemcitabine

Intervention Type: DRUG

1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)

capecitabine

Intervention Type: DRUG

starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)

Interventions

gemcitabine

1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)

Intervention Type: DRUG

capecitabine

starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)

Intervention Type: DRUG

Other Intervention Names

gemzar; xeloda

Eligibility Criteria

Inclusion Criteria

• Histologically-confirmed pancreatic adenocarcinoma or biliary tract carcinoma (cholangiocarcinoma or gallbladder cancer)
• Disease must not be amenable to surgical resection. Patients with either locally advanced or metastatic disease are eligible
• No prior systemic therapy for their diagnosis
• ECOG performance score of 0-1
• Evidence of either or both of the following:

1. RECIST-defined measurable disease (lesions that can be accurately measured in at least one dimension with the longest diameter ≥ 20mm using conventional techniques or ≥10 mm with spiral CT scan)

2. An elevated serum CA19-9 at baseline ( ≥ 2X ULN)

• Female patients must be either surgically sterile or postmenopausal, or if of childbearing potential must have a negative pregnancy test (serum or urine) prior to enrollment and agree to use effective barrier contraception during the period of therapy. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the investigator.
• Adequate bone marrow function:

1. ANC ≥ 1500/uL

2. platelet count ≥ 100,000/uL

3. hemoglobin ≥ 9.0 g/dL

• Adequate hepatic function:

1. Total bilirubin ≤ 1.5 X ULN

2. AST (SGOT) ≤ 2.5 X ULN

3. ALT (SGPT) ≤ 2.5 X ULN

• Adequate renal function as determined by either:

1. Calculated or measured creatinine clearance ≥ 40 mL/min (for calculated creatinine clearance, Cockroft-Gault equation will be used)

2. Serum creatinine ≤ 1.5 X ULN

• Ability to swallow oral medications
• Ability to understand the nature of this study protocol and give written informed consent
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria

• Any prior systemic or investigational therapy for metastatic or locally advanced pancreatic cancer or biliary cancer. Systemic therapy administered alone or in combination with radiation in the adjuvant setting is permissible as long as it was completed > 6 months prior to the time of study enrollment.
• Inability to comply with study and/or follow-up procedures.
• History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that, in the opinion of the investigator, renders the subject at high risk from treatment complications or might affect the interpretation of the results of the study.
• Presence of central nervous system or brain metastases.
• Pregnancy (positive pregnancy test) or lactation.
• Prior malignancy except for adequately treated basal cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other form of cancer from which the patient has been disease-free for 5 years.
• Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.
• Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.
• Known, existing uncontrolled coagulopathy.
• Major surgery within 4 weeks of the start of study treatment, without complete recovery.
• Concurrent/pre-existing use of coumadin.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Comprehensive Cancer Network

NETWORK

Sponsor Role: collaborator

University of California, San Francisco

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrew Ko, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States

Huntsman Cancer Center, University of Utah

Salt Lake City, Utah, United States

Countries

United States

Other Identifiers

CC#074510

Identifier Type: -

Identifier Source: org_study_id